PentaBind's therapeutic drugs made with aptamers and generative AI solve a decades old problem of targeting 'undruggable' proteins; a new hope to drug the remaining 85% of proteins in the human proteome that we don't currently have drugs for. PentaBind's unique competitive advantage lies in their invented wet-lab methods to generate training data for their AI, enabling them to design aptamers in 20x reduced time and 20x reduced cost compared to traditional aptamer design.